Biotechnological Innovations to Combat Antimicrobial Resistance and Advance Global Health Equity.
| dc.contributor.author | Rugarabamu, Sima | |
| dc.contributor.author | Mwanyika, Gaspary | |
| dc.date.accessioned | 2026-04-14T06:11:45Z | |
| dc.date.available | 2026-04-14T06:11:45Z | |
| dc.date.issued | 2025-09-05 | |
| dc.description | This Journal Article of Health Sciences and Technology was published by MDPI in 2025. | |
| dc.description.abstract | Antimicrobial resistance (AMR) is a growing global health emergency that threatens the effectiveness of modern medicine, exacerbating healthcare costs, morbidity, and mortality, particularly in low- and middle-income countries (LMICs). Traditional approaches to antimicrobial development and stewardship have proven inadequate in curbing the rapid emergence and spread of resistant pathogens. This review explores cutting-edge biotechnological innovations as sustainable, precision-based solutions to combat AMR and promote global health equity. A comprehensive narrative review was conducted using literature published between 2018 and 2023 from PubMed, ScienceDirect, and Web of Science. Peer-reviewed studies focusing on novel antimicrobial strategies were thematically analyzed, with attention to efficacy, feasibility, and translational readiness. Key innovations identified include nanotechnology-enhanced antimicrobial delivery, bacterio-phage therapy, CRISPR-Cas gene editing, immunotherapy, and personalized medicine.These strategies demonstrated substantial in vitro and in vivo efficacy, such as >90% MRSA biofilm reduction via silver nanoparticles and 95% carbapenem susceptibility restoration in E. coli using CRISPR-Cas9. When integrated with machine learning and rapid diagnostics, these approaches enable precision-targeted therapies and data-informed stewardship, offering scalable solutions adaptable to diverse healthcare systems. Antimicrobial resistance demands urgent, equitable innovation. Integrating biotechnologies like CRISPR, phage therapy, and nanomedicine with data-driven tools offers promising solutions. To ensure real-world impact, we recommend establishing regionally tailored translational research platforms and public–private partnerships as the most effective strategy to scale innovations and strengthen AMR response in low-resource settings. | |
| dc.description.sponsorship | Mbeya University of Science and Technology. | |
| dc.identifier.other | https://doi.org/10.3390/ bacteria4030046 | |
| dc.identifier.uri | https://repository.must.ac.tz/handle/123456789/546 | |
| dc.language.iso | en | |
| dc.publisher | MDPI | |
| dc.title | Biotechnological Innovations to Combat Antimicrobial Resistance and Advance Global Health Equity. | |
| dc.type | Article |